ChemGenex Pharmaceuticals Limited

LONDON - New Clinical Data Presented at EHA Suggests That Omacetaxine May Provide a Useful Treatment Option for CML Patients Resistant to Multiple TKI Therapies ChemGenex Pharmaceuticals Limited (ASX:CXS) announced that positive, updated data from its phase 2/3 clinical trial study of omacetaxine in chronic myeloid leukemia (CML) patients with resistance to multiple tyrosine kinase inhibitors (TKIs) was presented at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany on Saturday.